US health panel recommends easing restrictions on controversial peptides
Vote from advisory group – whose members include people linked to peptides industry – likely to embolden RFK Jr A panel of federal health advisers on Thursday narrowly recommended easing access to several peptides popular with wellness influencers and celebrities, despite warnings from government scientists that the chemicals have not been shown to be safe or effective. In a series of votes, outside experts to the Food and Drug Administration advised the agency to drop current restrictions barring pharmacies from producing injectable peptides with names like BPC-157, TB-500 and KPV. Continue reading...
A panel of federal health advisers on Thursday narrowly recommended easing access to several peptides popular with wellness influencers and celebrities, despite warnings from government scientists that the chemicals have not been shown to be safe or effective.
In a series of votes, outside experts to the Food and Drug Administration advised the agency to drop current restrictions barring pharmacies from producing injectable peptides with names like BPC-157, TB-500 and KPV.
The panel’s vote is not binding but is likely to embolden the health secretary, Robert F Kennedy Jr, who has described himself as a “big fan” of peptides and vowed to overturn FDA restrictions put in place under Joe Biden.
Across several votes, the panelists voted 8-6, with one abstention, in favor of putting the peptides on FDA’s list of substances considered safe for pharmacy compounding.
BOLD.news retains normalized extraction for time-stamped evidence and analysis. This public wrapper shows a limited excerpt because availability is not a republication license; use the publisher link for the complete presentation.